Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC36 in Adult Participants With Obesity or Overweight
NCT07893106Phase 1Recruiting
- Sponsor
- Ascletis Pharma Inc.
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC36 in obesity (8 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse Events up to 10 weeks. Started Oct 2026; status: recruiting.
02
Drugs
ASC36
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07893106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893106.